Collaboration is required for successful immunotherapy

Slides:

Advertisements

Similar presentations

Isotype control Supplementary Figure S1. Strategy for gating CD11b+CD14-CD33+CD40+ myeloid cells. Singlets were gated from live cells shown in forward.

Advertisements

Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.

CD4 T cells: fates, functions, and faults by Jinfang Zhu, and William E. Paul Blood Volume 112(5): September 1, 2008 ©2008 by American Society.

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

CD8 + T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia by Li Ma, Elisa Simpson,

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma by Maurizio Chiriva-Internati, Zhiqing Wang, Emanuela Salati, Klaus.

ایمونولوژی سرطان پزشکی -آذرماه 1387.

Doina M. Racila, MD, Joel N. Kline, MD, MSc

Hepatic AAV Gene Transfer and the Immune System: Friends or Foes?

The beauty of TLR agonists for CTCL

GVHD-associated immunodeficiency: soil or seed?

Immunotherapy of hepatocellular carcinoma

MBL: mostly benign lymphocytes, but…

“Vitamin hypothesis”: explanation for allergy increase?

Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine.

Positioning NK-κB in multiple myeloma

Next-generation leukemia immunotherapy

by Venetia Bigley, Laura E. Spence, and Matthew Collin

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

by Zhenping Zhu Blood Volume 108(6): September 15, 2006

Glis: novel modulators of TCR signaling?

Rituximab-induced tumor cell agglutination

Tax fingerprint in adult T-cell leukemia

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets by Kartik Sehgal,

Cancer Immunotherapy by Dendritic Cells

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

T regulatory cells turn on T regulatory cells

CMV: when bad viruses turn good

Engineering regulatory T cells against factor VIII inhibitors

In situ identification of allospecific B cells using pentamers

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Taking a leaf from the book of oral tolerance

Has the T cell bitten off more than it can chew?

by Edward S. Morris, Kelli P. A. MacDonald, and Geoffrey R. Hill

Treg's Alter Ego: An Accessory in Tumor Killing

by Robert McMillan, Jennifer Lopez-Dee, and Joseph C. Loftus

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 by Maria Wysocka, Bernice M. Benoit, Sarah.

Stage C or not stage C…? by Claire Dearden Blood

Malaria Vaccine Design: Immunological Considerations

Colorectal cancer vaccines: Principles, results, and perspectives

by Ineke J. M. ten Berge, and René A. W. van Lier

Antigen targeting to endosomal pathway in dendritic cell vaccination activates regulatory T cells and attenuates tumor immunity by Mikael Maksimow, Mari.

Close Encounters of the Tertiary Kind

Immunotherapy for acute lymphoblastic leukemia: from famine to feast

Immunotherapy of aspergillosis

Low-dose cyclophosphamide (Cy) reduces intratumoral Treg numbers and promotes enhanced T-cell trafficking and activation within the tertiary lymphoid aggregates.

Immunity to infectious agents

Delayed immune reconstitution after allogeneic transplantation increases the risks of mortality and chronic GVHD by Nelli Bejanyan, Claudio G. Brunstein,

The Immune Response to Skin Trauma Is Dependent on the Etiology of Injury in a Mouse Model of Burn and Excision Samantha M. Valvis, Jason Waithman, Fiona.

Regulatory T cells and cancer: an undesired tolerance

BTLA+ Dendritic Cells: The Regulatory T Cell Force Awakens

Figure 1 Mechanisms of oncolytic-virus-based cancer therapy

Maria A. Curotto de Lafaille, Juan J. Lafaille Immunity

Dendritic cells and innate immunity in kidney transplantation

Jürgen C. Becker, David Schrama Journal of Investigative Dermatology

Close Encounters of the Tertiary Kind

Volume 26, Issue 4, Pages (April 2018)

Volume 30, Issue 2, Pages (February 2009)

521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS Brad E. Hoffman Molecular.

Natural Killer T Cells: An Unconventional T-Cell Subset with Diverse Effector and Regulatory Functions Anna Balato, Derya Unutmaz, Anthony A. Gaspari

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

Releasing the Brakes on Cancer Immunotherapy

Anti-CD20-IL-21 fusokine: the tail wags the dog

Model of the accumulation of Treg cells in human tumors.

Increase in proliferation and activation of immune cells in peripheral blood after NKTR-214 treatment. Increase in proliferation and activation of immune.

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

Schematic representations of pulmonary hypertension.

Patient Tregs express normal levels of suppression.

Cartoon of OV-mediated effects in tumor.

Presentation transcript:

Collaboration is required for successful immunotherapy by Soldano Ferrone, and Eric Ko Blood Volume 107(8):3025-3026 April 15, 2006 ©2006 by American Society of Hematology

Enhanced tumor antigen–specific CTL response is generated by cross talk between NK cells, DCs, and CD8+ T cells and reduction in CD4+CD25+ T regulatory (Treg) cell numbers at the priming site. Enhanced tumor antigen–specific CTL response is generated by cross talk between NK cells, DCs, and CD8+ T cells and reduction in CD4+CD25+ T regulatory (Treg) cell numbers at the priming site. Immunization strategies that trigger the innate and adaptive arms of the immune system and reduce the number of Treg cells generate a more effective tumor antigen–specific CTL response (left panel) than those that trigger only the adaptive arm of the immune system (right panel). Soldano Ferrone, and Eric Ko Blood 2006;107:3025-3026 ©2006 by American Society of Hematology